Fundraising FoxGenesis Therapeutics, Inc.
Burlingame, US · Founded 2019 · 1 known investors
Find your way into Genesis Therapeutics, Inc.
Sign up to see every warm intro you have to Genesis Therapeutics, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Genesis Therapeutics, Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
EF
EVAN FEINBERGNamed on SEC filing
LB
LEONARD BELLNamed on SEC filing
PP
PEPTIBOON PRASITNamed on SEC filing
KJ
KRIS JENNERNamed on SEC filing
NS
NICHOLAS STOCKNamed on SEC filing
BS
BENJAMIN SKLAROFFNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$297.4M disclosed across 3 rounds · 2020–2023
▶$224MraisedAug 2023 · 50 investors · BiotechnologyRule 506(b)
▶$224MraisedAug 2023 · 50 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- VIJAY PANDEDirector
- EVAN FEINBERGExecutive Officer, Director
- PEPTIBOON PRASITExecutive Officer, Director
- WILLIAM MCCARTHYExecutive Officer
- LEONARD BELLDirector
- KRIS JENNERDirector
- BENJAMIN SKLAROFFExecutive Officer
- Offering amount
- $224M
- Amount sold
- $224M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$23.9MraisedDec 2022 · 33 investors · BiotechnologyRule 506(b)
▶$23.9MraisedDec 2022 · 33 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- STEPHEN DANNExecutive Officer
- KRIS JENNERDirector
- BENJAMIN SKLAROFFExecutive Officer
- EVAN FEINBERGExecutive Officer, Director
- WILLIAM MCCARTHYExecutive Officer
- PEPTIBOON PRASITDirector
- LEONARD BELLDirector
- Offering amount
- $23.9M
- Amount sold
- $23.9M
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$49.5MraisedDec 2020 · 24 investors · BiotechnologyRule 506(b)
▶$49.5MraisedDec 2020 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- EVAN FEINBERGExecutive Officer, Director
- LEONARD BELLDirector
- PEPTIBOON PRASITDirector
- KRIS JENNERDirector
- NICHOLAS STOCKExecutive Officer
- BENJAMIN SKLAROFFExecutive Officer
- Amount sold
- $49.5M
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Genesis Therapeutics, Inc.'s investors?
- Genesis Therapeutics, Inc.'s investors include Andreessen Horowitz.
- How much funding has Genesis Therapeutics, Inc. raised?
- Genesis Therapeutics, Inc. has disclosed $297.4M raised across 3 rounds.
- Where is Genesis Therapeutics, Inc. headquartered?
- Genesis Therapeutics, Inc. is headquartered in Burlingame, US.